| 张秋宁,田金徽,李倩茹,刘锐锋,张红,杨燕,王小虎.碳离子治疗Ⅰ期非小细胞肺癌的Meta分析[J].中华放射医学与防护杂志,2016,36(8):594-600 |
| 碳离子治疗Ⅰ期非小细胞肺癌的Meta分析 |
| A Meta-analysis of carbon ion radiotherapy for stage I non-small cell lung cancer |
| 投稿时间：2016-03-22 |
| DOI：10.3760/cma.j.issn.0254-5098.2016.08.008 |
| 中文关键词: 碳离子 非小细胞肺癌 Meta分析 |
| 英文关键词:Carbon ion Non-small cell lung cancer Meta-analysis |
| 基金项目:国家自然科学基金（81160283，81372419） |
|
| 摘要点击次数: 2310 |
| 全文下载次数: 2155 |
| 中文摘要: |
| 目的 评价碳离子治疗Ⅰ期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法 检索PubMed、Cochrane library、EMBASE、中国期刊全文数据库、中国生物医学文献数据库、万方数据库，收集碳离子治疗Ⅰ期NSCLC的研究，提取数据，对满足条件的数据采用MetaAnalyst Beta 3.13和STATA 12.0进行合并分析。结果 共纳入10个研究（7个临床试验），Meta分析结果显示，1、3和5年的总生存率分别为95.1%、68.5%和45.9%；1、3和5年的局部控制率分别为90.2%、76.7%和81.2%；1、3和5年的肿瘤特异生存率分别为82.9%、58.5%和57.3%；总复发率和原发肿瘤复发率分别为45.8%和11%；总死亡率、肺癌特异性死亡率分别为52.4%、28.3%；T1和T2期的NSCLC在5年总生存率、总复发率、肺癌特异性死亡率、皮肤1级和2级不良反应差异有统计学意义。结论碳离子治疗Ⅰ期NSCLC 是一种安全有效的治疗方法，具有广阔的临床应用前景。碳离子治疗作为一种国际标准化的治疗方法应用于NSCLC患者前，尚需进行高质量、大样本的临床研究。 |
| 英文摘要: |
| Objective To assess the efficacy and safety of the carbon ion radiotherapy for stage I non-small cell lung cancer (NSCLC). Methods We searched multiple electronic bibliographic databases, including the Cochrane library, PubMed, EMBASE, China Journal Full-text Database, Chinese Biomedical Database, and the Wanfang Database to assemble the available studies of carbon ion radiotherapy for stage I non-small cell lung cancer. MetaAnalyst Beta 3.13 and STATA 12.0 software were used to combine the extracted data. Results Ten studies (seven trials) were included. The overall survival rates of 1, 3 and 5 years were 95.1%, 68.5% and 45.9%, respectively. The local control rates of 1, 3 and 5 years were 90.2%, 76.7% and 81.2%, respectively. The cause specific survival rate of 1, 3 and 5 years were 82.9%, 58.5% and 57.3%, respectively. The rate of primary recurrence and total recurrence were 45.8% and 11%, respectively. The rates of total death and death from lung cancer were 52.4% and 28.3%, respectively. There were differences observed between T1 stage and T2 stage in regards to five year overall survival rate, total recurrence, lung cancer death, and grade 1 and grade 2 skin toxicities. Conclusions Available data demonstrate that carbon ion radiotherapy, in general, is a safe and feasible treatment modality for stage I NSCLC. Although current results are promising, more evidence is required before carbon ion radiotherapy can become the international standard treatment for lung cancer patients. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|